肠道菌群及其代谢物与肺动脉高压相关性的研究进展

Research advances in the association of gut microbiota and its metabolites with pulmonary arterial hypertension

摘要

肺动脉高压（pulmonary arterial hypertension，PAH）是一种恶性进展性肺血管疾病，特征是肺动脉周围炎症和肺动脉重塑，与多种心血管和呼吸系统等疾病有关，发病机制尚不明确。日益增多的证据表明PAH患者具有独特的肠道菌群组成，肠道菌群及其代谢产物在PAH的发生与发展中发挥重要作用。本文将综述肠道菌群及其代谢物在PAH发病中的作用，介绍基于肠道菌群及代谢物的新兴治疗方法（如粪便微生物移植、益生菌、补充短链脂肪酸）的研究进展。

Abstract

Pulmonary arterial hypertension（PAH） is a malignant progressive pulmonary vascular disease characterized by perivascular inflammation and pulmonary artery remodeling and is associated with various cardiovascular and respiratory diseases，with an unclear pathogenesis. Increasing evidence indicates that patients with PAH have a distinct composition of gut microbiota，and gut microbiota and its metabolites play a crucial role in the development and progression of PAH. This article reviews the role of gut microbiota and its metabolites in the pathogenesis of PAH and introduces the research advances in emerging therapies based on gut microbiota and its metabolites，such as fecal microbiota transplantation，probiotics，and supplementation of short-chain fatty acids.

关键词

肺动脉高压 / 肠道微生物 / 肠道菌群代谢物

Key words

pulmonary arterial hypertension / gut microbiota / gut microbiota metabolites

基金资助

国家自然科学基金资助项目(82060018;81700438)

云南省科技计划资助项目(202301AY070001-300;202101AS070043;202102AA310003-7;202105AF150019)